Glutathione pegylated liposomal methylprednisolone administration after the early phase of status epilepticus did not modify epileptogenesis in the rat

Holtman, Linda; Vliet, Erwin A. van; Appeldoorn, Chantal C.M.; Gaillard, Pieter J.; Boer, Marco de; Dorland, Rick; Wadman, Wytse J.; Gorter, Jan A.

doi:10.1016/j.eplepsyres.2014.01.010

Cited by 13 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In summary, these correlative studies demonstrate a potential relationship between selective augmentation of subsets of inflammatory mediators after eFSE and epilepsy. Blocking inflammation as a whole ( Holtman et al, 2014 ) has proven unhelpful for aborting epilepsy, as have a number of studies targeting specific pathways in the inflammatory molecular network ( Holtman et al, 2009 ; Vezzani et al, 2011 ; Noe et al, 2013 ). Indeed, rather than being pathogenic, it is possible that some observed inflammatory responses may be neuroprotective against the epileptogenic process, as has been described for other disorders ( Schwartz and Kipnis, 2005 ).…”

Section: Discussionmentioning

confidence: 99%

“…Inflammation has been implicated in many animal models of acquired epilepsy, although its role in epileptogenesis remains unclear ( Holtman et al, 2009, 2010 ; Vezzani et al, 2011 , 2008 ). Fever, the initiator of FSE, intrinsically involves inflammation and the cytokine interleukin (IL)-1β is a crucial component in eFSE generation ( Dubé et al, 2005 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rapid, Coordinate Inflammatory Responses after Experimental Febrile Status Epilepticus: Implications for Epileptogenesis

Patterson

Brennan

Curran

et al. 2015

eneuro

View full text Add to dashboard Cite

Epilepsy is a common neurological disorder with many causes. For temporal lobe epilepsy, antecedent insults are typically found. These risk factors include trauma or history of long fever-associated seizures (febrile status epilepticus) in childhood. Whereas the mechanisms by which such insults promote temporal lobe epilepsy are unknown, an extensive body of work has implicated inflammation and inflammatory mediators in both human and animal models of the disorder. However, direct evidence for an epileptogenic role for inflammation is lacking. Here we capitalized on a model where only a subgroup of insult-experiencing rodents develops epilepsy. We reasoned that if inflammation was important for generating epilepsy, then early inflammation should be more prominent in individuals destined to become epileptic compared with those that will not become epileptic. In addition, the molecular and temporal profile of inflammatory mediators would provide insights into which inflammatory pathways might be involved in the disease process. We examined inflammatory profiles in hippocampus and amygdala of individual rats and correlated them with a concurrent noninvasive, amygdalar magnetic resonance imaging epilepsy-predictive marker. We found significant individual variability in the expression of several important inflammatory mediators, but not in others. Of interest, a higher expression of a subset of hippocampal and amygdalar inflammatory markers within the first few hours following an insult correlated with the epilepsy-predictive signal. These findings suggest that some components of the inflammatory gene network might contribute to the process by which insults promote the development of temporal lobe epilepsy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Rapid, Coordinate Inflammatory Responses after Experimental Febrile Status Epilepticus: Implications for Epileptogenesis

Patterson

Brennan

Curran

et al. 2015

eneuro

View full text Add to dashboard Cite

show abstract

“…Liposome nanotechnology has enabled sustained delivery systems of glucocorticoids for epilepsy treatment, enhancing therapeutic efficacy [ 53 ]. The integration of mass spectrometry, genomics advancements, and nanotechnology has facilitated cost-effective expanded newborn screening, enabling the detection of a wider range of disorders in inborn errors of metabolism [ 54 ].…”

Section: Nanotechnology In Other Pediatric Related Areasmentioning

confidence: 99%

“…In the field of pediatric medicine, nanotechnology offers innovative solutions for the diagnosis and treatment of various conditions. It has shown promise in epilepsy, expanded newborn screening, cardiovascular diseases, neuroinflammation, neurodegenerative diseases, gestational diabetes, bone disorders, mosquito-borne diseases, micronutrient deficiency, vulvovaginitis, and more [ 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 ]. Nanotechnology holds potential for tissue engineering, personalized nanomedicine, scoliosis, respiratory tract disorders, neurosensory diseases, and infections [ 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 ].…”

Section: Introductionmentioning

confidence: 99%

Exploring the Potential of Nanotechnology in Pediatric Healthcare: Advances, Challenges, and Future Directions

Omidian

Mfoafo

2023

Pharmaceutics

View full text Add to dashboard Cite

The utilization of nanotechnology has brought about notable advancements in the field of pediatric medicine, providing novel approaches for drug delivery, disease diagnosis, and tissue engineering. Nanotechnology involves the manipulation of materials at the nanoscale, resulting in improved drug effectiveness and decreased toxicity. Numerous nanosystems, including nanoparticles, nanocapsules, and nanotubes, have been explored for their therapeutic potential in addressing pediatric diseases such as HIV, leukemia, and neuroblastoma. Nanotechnology has also shown promise in enhancing disease diagnosis accuracy, drug availability, and overcoming the blood–brain barrier obstacle in treating medulloblastoma. It is important to acknowledge that while nanotechnology offers significant opportunities, there are inherent risks and limitations associated with the use of nanoparticles. This review provides a comprehensive summary of the existing literature on nanotechnology in pediatric medicine, highlighting its potential to revolutionize pediatric healthcare while also recognizing the challenges and limitations that need to be addressed.

show abstract

“…[ 61 ] However, compared to plain liposomes such as Doxil, the number of targeted liposomes that entered the clinical stage is fewer, including MM‐302 (targeting HER2 receptor using an anti‐ErbB2‐scFv for treatment of breast cancer), [ 2 , 62 ] 2B3‐101 (targeting glutathione receptor at the blood‐brain barrier for treatment of glioma and brain metastases), [ 63 ] and MBP‐426 (transferrin‐modified liposomes for gastric, gastroesophageal, or esophageal adenocarcinoma). [ 64 ] Meanwhile, a growing number of contradictory literature suggests that active targeting strategies do not eventually result in enhanced tumor accumulation. [ 8 ] The connection between the “off‐target” effect of nanomedicines and the formation of protein coronas has not been observed until recent years.…”

Section: Igm Dominating In Vivo Performance Of Liposomesmentioning

confidence: 99%

Interplay between Liposomes and IgM: Principles, Challenges, and Opportunities

Wang

Lin

et al. 2023

Advanced Science

View full text Add to dashboard Cite

Liposomes have received tremendous attention as a class of versatile pharmaceutical vehicles of great potential over the past several decades. However, the application of liposomes encounters major challenges due to the knowledge gaps in their in vivo delivery process. Immunoglobulin M (IgM) displays both pervasiveness and complexity in regulating the biological functions as well as eliciting adverse effects of liposomes. Understanding, mitigating, and exploiting the duality of IgM are prerequisites for achieving various biomedical applications of liposomes. In this review, the intricate relationship between liposomes and their biological environments has been summarized, with an emphasis on the regulatory effects of IgM on in vivo performance of liposomes. Corresponding solutions have also been discussed to evade IgM‐mediated opsonization for safe and efficient drug delivery.

show abstract

Glutathione pegylated liposomal methylprednisolone administration after the early phase of status epilepticus did not modify epileptogenesis in the rat

Cited by 13 publications

References 29 publications

Rapid, Coordinate Inflammatory Responses after Experimental Febrile Status Epilepticus: Implications for Epileptogenesis

Rapid, Coordinate Inflammatory Responses after Experimental Febrile Status Epilepticus: Implications for Epileptogenesis

Exploring the Potential of Nanotechnology in Pediatric Healthcare: Advances, Challenges, and Future Directions

Interplay between Liposomes and IgM: Principles, Challenges, and Opportunities

Contact Info

Product

Resources

About